N/A
N=22
Dexmedetomidine and Adenosine: Therapeutic Use for SVT
Supraventricular Tachycardia
Bottom Line
View on ClinicalTrials.gov: NCT01495481 ↗Enrolled (actual)
22
Serious AEs
0.0%
Results posted
Mar 2017
Primary outcome: Primary: Termination of SVT — 16; 21 participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Dexmedetomidine (Drug); Adenosine (Drug)
- Age
- Pediatric, Adult · 5+ yrs
- Sex
- All
- Sponsor
- University of Pittsburgh
- Primary completion
- Jul 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Termination of SVT |
16; 21 | — |
| SECONDARY Number of Participants With Sinus Pause >2.5 Sec After Termination of SVT |
0; 16 | — |
| SECONDARY Number of Participants With Tachyarrhythmias After Medication Administration |
0; 0 | — |
| SECONDARY Number of Participants With Hypotension by Non-invasive Cuff in First 10 Minutes After Medication Administration |
1; 0 | — |
Summary
The purpose of this study is to evaluate the efficacy and safety of dexmedetomidine in the acute termination of Supraventricular Tachycardia (SVT).
Eligibility Criteria
Inclusion Criteria
- Patients between the age of 5 - 30 years old, who are scheduled for cardiac electrophysiology study for evaluation of reentrant SVT
Exclusion Criteria
- Severe Heart Failure
- Presence of of any other antiarrhythmic medication within 24 hours of enrollment
- Third degree heart block
- Sick Sinus Syndrome
Data sourced from ClinicalTrials.gov (NCT01495481). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.